Details
Stereochemistry | ACHIRAL |
Molecular Formula | C19H20N2O3 |
Molecular Weight | 324.3737 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)(OCC1=NN(CC2=CC=CC=C2)C3=C1C=CC=C3)C(O)=O
InChI
InChIKey=MTHORRSSURHQPZ-UHFFFAOYSA-N
InChI=1S/C19H20N2O3/c1-19(2,18(22)23)24-13-16-15-10-6-7-11-17(15)21(20-16)12-14-8-4-3-5-9-14/h3-11H,12-13H2,1-2H3,(H,22,23)
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/19592568Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/15691869
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19592568
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/15691869
Bindarit (2-Methyl-2-[[1-(phenylmethyl)-1H-indazol-3yl]methoxy]propanoic acid; AF-2838) is an indazolic derivative that is devoid of any immunosuppressive effects and has no effect on arachidonic acid metabolism. It has been proved to have anti-inflammatory activity in a number of experimental diseases, including pancreatitis, arthritis, and lupus nephritis. This therapeutic effect has been associated with its ability to interfere selectively with monocyte recruitment, although the underlying molecular mechanisms are unknown. Bindarit selectively inhibits the production of the monocyte chemotactic protein subfamily of CC inflammatory chemokines (MCP-1/CCL2, MCP-3/CCL7, MCP-2/CCL8) without affecting the production of the cytokines IL-1, IL-6, or the chemokines IL-8, MIP-1α.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL3217391 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18775807 |
|||
Target ID: CHEMBL1649052 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18775807 |
|||
Target ID: P80075 Gene ID: 6355.0 Gene Symbol: CCL8 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/18775807 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | Unknown Approved UseUnknown |
|||
Palliative | Unknown Approved UseUnknown |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
50 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21852559 |
25 mg/kg single, oral dose: 25 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
BINDARIT plasma | Sus scrofa population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
10 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21852559 |
25 mg/kg single, oral dose: 25 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
BINDARIT plasma | Sus scrofa population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
600 mg 2 times / day multiple, oral Highest studied dose Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Sources: Page: p.370 |
unhealthy, ADULT n = 11 Health Status: unhealthy Condition: lupus nephritis Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 11 Sources: Page: p.370 |
Sample Use Guides
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/15691869
Acini were preincubated with/without bindarit (460 μM) for 30 min, and further incubated with caerulein (10−12-10−7 M) for 30 min. The dose of bindarit was chosen based on earlier reports in which it was shown to inhibit MCP-1 synthesis. Bindarit has been shown to preferentially inhibit MCP-1 production in vitro in monocytes without affecting the production of the cytokines IL-1, IL-6, or the chemokines IL-8, protein macrophage inflammatory-1alpha.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29634
Created by
admin on Fri Dec 15 15:40:29 GMT 2023 , Edited by admin on Fri Dec 15 15:40:29 GMT 2023
|
||
|
FDA ORPHAN DRUG |
110097
Created by
admin on Fri Dec 15 15:40:29 GMT 2023 , Edited by admin on Fri Dec 15 15:40:29 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB05834MIG
Created by
admin on Fri Dec 15 15:40:29 GMT 2023 , Edited by admin on Fri Dec 15 15:40:29 GMT 2023
|
PRIMARY | |||
|
100000085886
Created by
admin on Fri Dec 15 15:40:29 GMT 2023 , Edited by admin on Fri Dec 15 15:40:29 GMT 2023
|
PRIMARY | |||
|
6689
Created by
admin on Fri Dec 15 15:40:29 GMT 2023 , Edited by admin on Fri Dec 15 15:40:29 GMT 2023
|
PRIMARY | |||
|
DB12739
Created by
admin on Fri Dec 15 15:40:29 GMT 2023 , Edited by admin on Fri Dec 15 15:40:29 GMT 2023
|
PRIMARY | |||
|
71354
Created by
admin on Fri Dec 15 15:40:29 GMT 2023 , Edited by admin on Fri Dec 15 15:40:29 GMT 2023
|
PRIMARY | |||
|
JQ11LH711M
Created by
admin on Fri Dec 15 15:40:29 GMT 2023 , Edited by admin on Fri Dec 15 15:40:29 GMT 2023
|
PRIMARY | |||
|
DTXSID30156660
Created by
admin on Fri Dec 15 15:40:29 GMT 2023 , Edited by admin on Fri Dec 15 15:40:29 GMT 2023
|
PRIMARY | |||
|
130641-38-2
Created by
admin on Fri Dec 15 15:40:29 GMT 2023 , Edited by admin on Fri Dec 15 15:40:29 GMT 2023
|
PRIMARY | |||
|
CHEMBL2107549
Created by
admin on Fri Dec 15 15:40:29 GMT 2023 , Edited by admin on Fri Dec 15 15:40:29 GMT 2023
|
PRIMARY | |||
|
C96701
Created by
admin on Fri Dec 15 15:40:29 GMT 2023 , Edited by admin on Fri Dec 15 15:40:29 GMT 2023
|
PRIMARY | |||
|
EE-27
Created by
admin on Fri Dec 15 15:40:29 GMT 2023 , Edited by admin on Fri Dec 15 15:40:29 GMT 2023
|
PRIMARY |
ACTIVE MOIETY